Wall Street is underestimating the opportunity for a cardiovascular medical device company's core product to penetrate the market, according to Morgan Stanley.
Analyst Patrick Wood upgraded shares of Shockwave Medical to overweight from in-line, saying the Street is misjudging the potential catalysts that could improve the sales outlook for its coronary IVL catheter used before stent implantation, and that consensus expectations look "too low."
Given this setup, Wood lifted his price target to $335 a share, reflecting 28% upside from Friday's close.
SWAV YTD mountain Share performance in 2023 Potential catalysts for Shockwave shares include an investor day, a favorable environment for medical technology and an extended timeline before it faces new competition, Wood said.
"We think recent coronary reimbursement improvements from CMS mean the market is underestimating the penetration opportunity over the coming 2-3 years," Wood wrote.
Persons:
Morgan Stanley, Patrick Wood, Wood, — CNBC's Michael Bloom
Organizations:
Shockwave, Centers, Medicare, Medicaid